GENE ONLINE|News &
Opinion
Blog

Generic Drug
Ranking & Reports Generic Drug
Investigate the Current Status of Rivaroxaban Generic Drug Application in China
2023-03-01
COVID-19 Generic Drug
If It Works, Replicate It: Generic COVID-19 Drugs
2022-03-28
Trials & Approvals Dry Eye
First Generic for Dry-eye Gets U.S. FDA Nod
2022-02-04
China
China Drugmaker Aims for First Generic Drug Approval of Novartis’ Tasigna in China
2021-09-24
Ranking & Reports
Mainstream Generic Drugs Become Stumbling Blocks for Drug Innovation: A Deepdive into China’s Patent Trends
2021-03-17
Deals
Perrigo Splits Businesses, Offloads Generic Division to Private Equity
2021-03-04
Taiwan’s TTY Biopharm Pushes for Clinical Trials of its Complex Cancer Generic Drugs in Europe
2021-02-10
LATEST
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
READ MORE
EVENT
2023-03-28
Reuters Events: Pharma USA 2023
Philadelphia, USA
2023-04-24
Cell & Gene Therapy Summit 2023
Brussels, Belgium
2023-04-28
Boston Chinese Investment Club 2023 Biotech Pitch Competition
Boston, USA
2023-11-16
3rd INTERNATIONAL CONFERENCE ON NUTRITION AND HEALTHCARE
Dubai, UAE
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2023 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top